• Journal of Digestive Cancer Research
• /
• 제10권2호
• /
• pp.74-81
• /
• 2022

Colorectal peritoneal metastasis has been an incurable disease for centuries. However, since the new millennium, recent advancements in therapies are achieved with modern chemotherapeutic agents, target agents, and immune checkpoint blockade introduction. Modern chemotherapies, from a nearly nonexistent median survival if untreated, have raised the duration to 16 months with target agents. Experts have once again surpassed its limit by introducing intraperitoneal chemotherapy and cytoreductive surgery (CRS). Numerous clinical trials regarding CRS and hyperthermic intraperitoneal chemotherapy have now opened new doors in peritoneal carcinomatosis treatment, even securing complete remission. In addition, up-to-date modalities, such as pressurized intraperitoneal aerosol chemotherapy and immunotherapies, showed promising results at an early stage.

• Journal of Gastric Cancer
• /
• 제9권2호
• /
• pp.51-56
• /
• 2009

목적: 위암의 복막재발 또는 암종증을 확진하기 위해서는 개복 수술 및 생검이 필요하다. 최근 시험적 개복술 대신 진단적 복강경 검사가 많이 시행되고 있으나 위암 환자에서 복막재발을 진단하기 위해 시험적 개복술 대신 진단적 복강경 검사로 대체한 것에 관한 연구는 아직 보고된 바가 적다. 이에 복막전이가 의심되는 위암환자에서 시행된 진단적 복강경 검사를 분석하여 그 역할과 유용성에 대해 검토하고자 한다. 대상 및 방법: 2004년 2월부터 2009년 3월까지 복막전이가 의심되어 진단적 복강경 검사를 시행 받은 총 45명의 위암 환자들에 대해 안전성과 정확도를 평가하였다. 결과: 총 45명의 연구 대상 환자들에서 남자는 26명(57.8%), 여자는 19명(42.2%)이었고 전체 평균 연령은 49.3세(25~74세)였다. 총 검사시간은 평균 $44.1\pm26.9$분, 술 후 재원기간은 평균 $2.7\pm2.8$일이었다. 45명 중 검사상 양성으로 나온 사람은 35명이었으며, 음성으로 나온 10명 중 위음성은 3명이었다. 검사 관련 합병증은 1건이었으며, 검사 관련 사망자는 없었다. 민감도는 진단적 복강경 검사의 경우 92.1%, 이학적 검사 29.7%, 복부 CT 86.5%, PET CT 69.2%. CEA 검사는 18.8%였다. 결론: 진단적 복강경 검사는 비교적 짧은 시술 시간과 재원기간, 낮은 합병증 발생율을 보여 시험적 개복술에 비해 안전한 검사이다. 또한 다른 검사에 비해 민감도가 높아 위암환자에서 복막 재발 및 암종증 여부를 확인하는데 효과적인 검사 방법으로 사료된다.

• Journal of Gastric Cancer
• /
• 제14권4호
• /
• pp.266-270
• /
• 2014

Purpose: Palliative gastrectomy and chemotherapy are important options for peritoneal seeding of gastric cancer. The treatment stage IV gastric cancer patient who respond to induction chemotherapy, is converted to gastrectomy (conversion therapy or conversion surgery). This study explored the clinical outcomes of gastric cancer patients with peritoneal seeding who had undergone conversion therapy. Materials and Methods: Between 2003 and 2012, gastric cancer patients with peritoneal seeding, as determined by preoperative or intraoperative diagnosis were reviewed retrospectively. Clinicopathologic characteristics and clinical outcomes of patients with peritoneal seeding were analyzed. Results: Forty-three patients were enrolled. Eighteen patients had undergone conversion surgery and 25 patients continued conventional chemotherapy. Among the 18 conversion patients, 10 received clinically curative resection. The median follow-up period was 28.5 months (range 8 to 60 months) and the total 3-year survival rate was 16.3%. The median survival time of the patients who received clinically curative conversion therapy was 37 months, and the 3-year survival rate was 50%. The median follow-up for non-curative gastrectomy patients was 18 months. No patient treated using chemotherapy survived to 3 years; the median survival time was 8 months. The differences in survival time between the groups was statistically significant (P<0.001). Conclusions: In terms of survival benefits for gastric cancer patients with peritoneal seeding, clinically curative conversion therapy resulted in better clinical outcomes.

• Asian Pacific Journal of Cancer Prevention
• /
• 제14권12호
• /
• pp.7289-7294
• /
• 2013

We here document discovery of a new and simple model of tumor seeding involving the mouse peritoneum. Irradiated tumor cells administered by i.p. injection provided effective vaccination against peritoneal carcinomatosis and distal metastasis with colorectal carcinomas. In flow cytometric analysis, CD4+ and CD8+ T lymphocytes, macrophages and myeloid-derived suppressor cells (MDSCs), which are easy to obtain in the peritoneal cavity, were revealed to have significant differences between immunized and non-immunized mice and these contributed to antitumor responses. We also observed that both serum and peritoneal lavage fluid harvested from immunized mice showed the presence of CT26-specific autoantibodies. In addition, increase in level of TGF-${\beta}1$ and IL-10 in serum but a decrease of TGF-${\beta}1$ in peritoneum was found. Taken together, these findings may provide a new vaccine strategy for the prevention of peritoneal and even systemic metastasis of carcinomas through induction of an autoimmune response in the peritoneum.

• Asian Pacific Journal of Cancer Prevention
• /
• 제17권2호
• /
• pp.539-543
• /
• 2016

Background: It is well known that peritoneal carcinomatosis (PC) from colorectal cancer (CRC) is associated with a poor prognosis. However, data on the prognostic significance of modern chemotherapy containing bevacizumab, cetuximab or panitumumab are not available. Materials and Methods: This retrospective review concerned 526 patients with metastatic CRC who were classified into two groups according to the presence or absence of PC, and were treated with systemic chemotherapy, with or without bevacizumab or anti-EGFR antibodies. The genetic background, in particular KRAS, BRAF, and PIK3CA gene mutations, and overall survival (OS) were compared between the two groups. Results: The median OS values were 23.3 and 29.1 months for PC and non-PC patients, respectively (hazard ratio [HR]=1.20; p=0.17). Among all patients, tumor location, number of metastatic sites and BRAF mutation status were significant prognostic factors, whereas the presence of PC was not. In the PC group, chemotherapy with bevacizumab resulted in a significantly longer OS than forchemotherapy without bevacizumab (HR=0.38, p<0.01), but this was not the case in the non-PC group (HR=0.80, p=0.10). Furthermore, the incidence of the BRAF V600E mutation was significantly higher in PC than in non-PC patients (27.7% versus 7.3%, p<0.01). BRAF mutations displayed a strong correlation with shorter OS in non-PC (HR=2.26), but not PC patients (HR=1.04). Conclusions: Systemic chemotherapy, especially when combined with bevacizumab, improved survival in patients with PC from CRC as well as non-PC patients. While BRAF mutation demonstrated a high frequency in PC patients, but it was not associated with prognosis.

• Parasites, Hosts and Diseases
• /
• 제50권4호
• /
• pp.345-347
• /
• 2012

Paragonimiasis is a parasitic disease caused by the lung fluke, Paragonimus spp. Lung flukes may be found in various organs, such as the brain, peritoneum, subcutaneous tissues, and retroperitoneum, other than the lungs. Abdominal paragonimiasis raises a considerable diagnostic challenge to clinicians, because it is uncommon and may be confused with other abdominopelvic inflammatory diseases, particularly peritoneal tuberculosis, and peritoneal carcinomatosis. Also, subcutaneous paragonimiasis does not easily bring up clinical suspicion, due to its rarity. We herein report 2 cases of abdominal paragonimiasis and 1 case of subcutaneous paragonimiasis in Korea.

• Asian Pacific Journal of Cancer Prevention
• /
• 제13권1호
• /
• pp.117-122
• /
• 2012

Aim: To elucidate the effects of hyperthermic $CO_2$ pneumoperitoneum on human gastric AGS cells. Methods: Based on a newly devised in vitro study model, we evaluated the anti-cancer effects of HT-$CO_2$ ($42-44^{\circ}C$ for 2-4h) on human gastric cancer cells, and also the corresponding mechanisms. Results: HT-$CO_2$ ($42-44^{\circ}C$ for 2-4h) severely inhibited cell proliferation as assessed by Cell Counting Kit-8 assay, while inducing apoptosis in a temperature- and time-dependent manner demonstrated by annexin-V/PI flow cytometry and morphological analysis (Hoechst/PI fluorescence). In addition, it was found that HT-$CO_2$ ($42-44^{\circ}C$ for 2-4h) promoted the up-regulation of Bax by western blotting. Significantly, it could also suppress gastric cancer cell invasion and metastasis by in vitro invasion and motility assay. Conclusion: In conclusion, HT-$CO_2$ had an efficacious cytotoxic effect on gastric cancer cells through Bax-induced mitochondrial apoptotic signaling. Our studies indicate that it may serve as a potential therapy for peritoneal carcinomatosis of gastric cancer. Further investigations in vivo using animal models are now urgently needed.

• 대한영상의학회지
• /
• 제82권2호
• /
• pp.335-346
• /
• 2021

장간막과 대망에서 원발성으로 생기는 종양은 비교적 흔하지 않지만, 종양과 비슷한 다양한 질환과의 감별이 필요한 경우가 많다. 또한, 다양한 복부 질환의 확산 경로이기 때문에 정확한 감별진단을 위해서는 장간막과 대망에 대한 해부학과 질병 종류 및 양상에 관하여 자세히 알아야 할 필요가 있다. 또한, 장간막과 대망의 숨어있는 병변들을 잘 찾아내어 적시에 정확한 치료를 하는 것이 중요하므로 복부 CT 판독 시 병변이 잘 생기는 부위를 잘 관찰하여야 한다.

• Journal of Yeungnam Medical Science
• /
• 제16권1호
• /
• pp.76-84
• /
• 1999

악성 복수와 비악성 복수의 감별 진단은 진단과 치료 과정에서 매우 중요한 역할을 한다. 많은 계측치들이 감별을 위하여 사용되어져 왔는데 어느 것도 단독 사용시 두 군을 완벽히 구분짓지는 못한다. 이에 본 연구자들은 악성복수와 비악성 복수의 감별에 있어서 여러 계측치들을 비교하여 민감도와 특이도가 높은 계측치를 찾고 이 결과를 토대로 악성복수와 비악성 복수의 구분에서 간단하면서도 효과적인 진단방법을 찾고자 하였다. 1995년 1월부터 1997년 12월까지 영남대학교 의과대학 부속병원 내과에 복수를 주소로 내원하여 복수 천자를 시행한 80명을 대상으로 이들 환자들을 악성 복수 환자군과 비악성 복수 환자군으로 나누어 조사하였다. 악성 복수군은 다시 암종증이 동반된 21명의 환자와 암종증의 증거가 없는 6명의 환자로 구분하였고 비악성 복수군은 다시 52명의 간경변증 환자군과, 1명의 간경변증이 없는 군으로 구분하였다. 모든 환자에게서 복수와 혈액에서 동시에 검체가 얻어졌고 계측치로 복수액의 콜레스테롤, CEA, LDH, 단백치, 세포진 검사, 복수액과 혈청의 LDH 비, 단백비, 혈청-복수액 알부민 차를 구하였고, 각 계측치의 평균을 구하여 두 군을 비교하였는데, 모든 계측치가 통계적으로 유의한 차이를 보여 주었다. 저자는 각 계측치마다 각 측정치를 적용하여 가장 높은 민감도와 특이도를 보이는, 즉 가장 높은 진단 능력을 나타내는 측정치를 절단치로 정한 후각 계측치에 적용하여 진 양성, 진 음성, 가 양성, 가 음성으로 분류한 후 민감도, 특이도, 양성 기대도, 음성 기대도, 진단 능력을 산출하였고, 연구된 계측치 중 민감도가 높은 계측치인 복수액의 콜레스테롤을 선별검사의 단계에 적용하고, 특이도가 높은 계측치인 세포진 검사와 복수와 혈청의 단백비를 악성 복수로 분류된 군에 적용하여 악성 복수를 확진하는 2단계 진단 과정을 80명의 환자들에게 적용하여 다음 결과를 얻었다. 1) 복수액 분석 결과 복수액의 콜레스테롤치가(절단치: 30 mg/dl) 93%의 가장 높은 민감도를 보였고, 복수액의 세포진 검사와 복수액과 혈청의 단백비가(절단치: 0.5) 100%, 98%의 가장 높은 특이도를 나타내었다. 2) 2단계의 진단 과정을 통하여 복강내 암종 전이가 확인된 21명 모두 악성 복수군으로 분류되었다. 3) 광범위한 간전이가 있는 악성 복수 모두 비악성군으로 분류되었다. 4) 간 경변증으로 인한 52례에서 모두 비악성군으로 분류되었다. 5) 전체 진단 과정을 통해 총 27명의 악성 복수 중 81.5%인 22명이 악성 복수군으로 진단되었다. 이상의 결과를 토대로 본 연구자들이 제시한 진단 과정은 악성 복수와 비악성 복수의 감별 진단에 효과적인 방법으로 생각되며 더욱 정확한 진단을 위해서는 임상 양상, 방사선학적 검사, 기타 검사 등을 토대로 종합적인 판단이 필요하리라 생각된다.

• Journal of Gastric Cancer
• /
• 제19권3호
• /
• pp.301-314
• /
• 2019

Purpose: Peritoneal carcinomatosis in gastric cancer (GC) patients results in extremely poor prognosis. Malignant ascites samples are the most appropriate biological material to use to evaluate biomarkers for peritoneal carcinomatosis. This study identified exosomal MicroRNAs (miRNAs) differently expressed between benign liver cirrhosis-associated ascites (LC-ascites) and malignant gastric cancer-associated ascites (GC-ascites), and validated their role as diagnostic biomarkers for GC-ascites. Materials and Methods: Total RNA was extracted from exosomes isolated from 165 ascites samples (73 LC-ascites and 92 GC-ascites). Initially, microarrays were used to screen the expression levels of 2,006 miRNAs in the discovery cohort (n=22). Subsequently, quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) analyses were performed to validate the expression levels of selected exosomal miRNAs in the training (n=70) and validation (n=73) cohorts. Furthermore, carcinoembryonic antigen (CEA) levels were determined in ascites samples. Results: The miR-574-3p, miR-181b-5p, miR-4481, and miR-181d were significantly downregulated in the GC-ascites samples compared to the LC-ascites samples, and miR-181b-5p showed the best diagnostic performance for GC-ascites (area under the curve [AUC]=0.798 and 0.846 for the training and validation cohorts, respectively). The diagnostic performance of CEA for GC-ascites was improved by the combined analysis of miR-181b-5p and CEA (AUC=0.981 and 0.946 for the training and validation cohorts, respectively). Conclusions: We identified exosomal miRNAs capable of distinguishing between non-malignant and GC-ascites, showing that the combined use of miR-181b-5p and CEA could improve diagnosis.